

20 January 2026

Dear Chairman Janigian, Vice Chairman Ulery, and Committee Members,

Thank you for the opportunity to provide testimony on behalf of Novocure in support of HB 1102, which would increase New Hampshire's Research & Development tax credit from \$50,000 to \$100,000. As a company deeply committed to innovation in the life sciences, we recognize the importance of policies that foster a strong research ecosystem and position New Hampshire as a leader in cutting-edge medical advancements.

Novocure, with our North American headquarters located in Portsmouth, understands that continued investment in research is critical to developing new treatment options for patients facing aggressive diagnoses. The state's R&D tax credit has been an important tool in supporting that work, enabling companies like ours to reinvest in innovation, grow our workforce, and contribute to New Hampshire's economy.

By expanding the credit, New Hampshire has an opportunity to further strengthen its life sciences sector, attract new investment, and support an ecosystem of companies—large and small—dedicated to developing breakthrough technologies. A more competitive R&D environment will not only benefit individual businesses but will also enhance the state's ability to retain top-tier talent, create high-paying jobs, and drive long-term economic growth.

Novocure strongly supports efforts to enhance New Hampshire's innovation economy and ensure the state remains a premier destination for life sciences. We appreciate the committee's attention to this important issue and urge your support for HB 1102.

Thank you for your time and consideration.

